Dawn of ocular gene therapy: Implications for molecular diagnosis in retinal disease

Science China Life Sciences

Volumn 56, Issue 2, 2013, Pages 125-133

  Zaneveld, Jacques ^a   Wang, Feng ^a   Wang, Xia ^a   Chen, Rui ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

APEX; Leber's Congenital Amarosis (LCA); molecular diagnosis; next generation sequencing (NGS); personal medicine; retinal disease; Retinitus Pigmentosa (RP); Stargardt disease

Indexed keywords

EID: 84873705425     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-013-4443-y     Document Type: Review

References (115)

1. Meyer U A. Personalized medicine: a personal view. Clin Pharmacol Ther, 2012, 91: 373-375.
2. Sieving P A, Caruso R C, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA, 2006, 103: 3896-3901.
3. Nguyen Q D, Schachar R A, Nduaka C I, et al. Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye, 2012.
4. Hauswirth W W, Aleman T S, Kaushal S, et al. Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther, 2008, 19: 979-990.
5. Cideciyan A V, Aleman T S, Boye S L, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA, 2008, 105: 15112-15117.
6. Bainbridge J W B, Smith A J, Barker S S, et al. Effect of gene therapy on visual function in Leber's Congenital Amaurosis. N Engl J Med, 2008, 358: 2231-2239.
7. Maguire A M, Simonelli F, Pierce E A, et al. Safety and efficacy of gene transfer for Leber's Congenital Amaurosis. N Engl J Med, 2008, 358: 2240-2248.
8. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med, 2012, 4: 120ra15.
9. Kinnunen K, Yla-Herttuala S. Gene therapy in age related macular degeneration and hereditary macular disorders. Front Biosci (Elite Ed), 2012, 4: 2546-2557.
10. Carter-Dawson L D, LaVail M M, Sidman R L. Differential effect of the rd mutation on rods and cones in the mouse retina. Invest Ophthalmol Vis Sci, 1978, 17: 489-498.
11. Weng J, Mata N L, Azarian S M, et al. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell, 1999, 98: 13-23.
12. Lem J, Flannery J G, Li T, et al. Retinal degeneration is rescued in transgenic rd mice by expression of the cGMP phosphodiesterase beta subunit. Proc Natl Acad Sci USA, 1992, 89: 4422-4426.
13. Bennett J, Tanabe T, Sun D, et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat Med, 1996, 2: 649-654.
14. Palfi A, Millington-Ward S, Chadderton N, et al. Adeno-associated virus-mediated rhodopsin replacement provides therapeutic benefit in mice with a targeted disruption of the rhodopsin gene. Hum Gene Ther, 2010, 21: 311-323.
15. -/- mouse model of retinitis pigmentosa. Hum Mol Genet, 2012.
16. Zhang K, Zhang L, Weinreb R N. Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov, 2012, 11: 541-559.
17. Daiger S P. Retinal Information Network. https://sph. uth. tmc. edu/retnet/, 1996.
18. den Hollander A I, Roepman R, Koenekoop R K, et al. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res, 2008, 27: 391-419.
19. Neveling K, Collin R W, Gilissen C, et al. Next-generation genetic testing for retinitis pigmentosa. Hum Mutat, 33: 963-972.
20. O'sullivan J, Mullaney B G, Bhaskar S S, et al. A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. J Med Genet, 49: 322-326.
21. Niederkorn J Y. Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? Front Immunol, 2012, 3: 148.
22. Friedmann T, Roblin R. Gene therapy for human genetic disease? Science, 1972, 175: 949-955.
23. Liu M M, Tuo J, Chan C C. Gene therapy for ocular diseases. Br J Ophthalmol, 2011, 95: 604-612.
24. Samulski R J, Berns K I, Tan M, et al. Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA, 1982, 79: 2077-2081.
25. Hermonat P L, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA, 1984, 81: 6466-6470.
26. Mori S, Wang L, Takeuchi T, et al. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology, 2004, 330: 375-383.
27. Klimczak R R, Koerber J T, Dalkara D, et al. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Muller cells. PLoS ONE, 2009, 4: e7467.
28. Zhong L, Li B, Mah C S, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA, 2008, 105: 7827-7832.
29. Vandenberghe L H, Auricchio A. Novel adeno-associated viral vectors for retinal gene therapy. Gene Ther, 2012, 19: 162-168.
30. Petrs-Silva H, Dinculescu A, Li Q, et al. High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther, 2008, 17: 463-471.
31. Kolstad K D, Dalkara D, Guerin K, et al. Changes in adeno-associated virus-mediated gene delivery in retinal degeneration. Hum Gene Ther, 2010, 21: 571-578.
32. Auricchio A, Kobinger G, Anand V, et al. Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum Mol Genet, 2001, 10: 3075-3081.
33. Pang J J, Dai X, Boye S E, et al. Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther, 2011, 19: 234-242.
34. Deng W T, Dinculescu A, Li Q, et al. Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal preservation in RCS rats. Invest Ophthalmol Vis Sci, 2012, 53: 1895-1904.
35. Acland G M, Aguirre G D, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet, 2001, 28: 92-95.
36. Mancuso K, Hauswirth W W, Li Q, et al. Gene therapy for red-green colour blindness in adult primates. Nature, 2009, 461: 784-787.
37. Yang Y, Mohand-Said S, Danan A, et al. Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. Mol Ther, 2009, 17: 787-795.
38. Min S H, Molday L L, Seeliger M W, et al. Prolonged recovery of retinal structure/function after gene therapy in an Rs1h-deficient mouse model of X-linked juvenile retinoschisis. Mol Ther, 2005, 12: 644-651.
39. Beltran W A, Cideciyan A V, Lewin A S, et al. Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci USA, 2012, 109: 2132-2137.
40. Koilkonda R D, Chou T H, Porciatti V, et al. Induction of rapid and highly efficient expression of the human nd4 complex i subunit in the mouse visual system by self-complementary adeno-associated virus. Arch Ophthalmol, 2010, 128: 876-883.
41. Zhang K, Hopkins J J, Heier J S, et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA, 2011, 108: 6241-6245.
42. Schwartz S D, Hubschman J P, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet, 2012, 379: 713-720.
43. Seiler M J, Aramant R B. Cell replacement and visual restoration by retinal sheet transplants. Prog Ret Eye Res, 2012, http://dx. doi. org/10. 1016/j. preteyeres. 2012. 06. 003.
44. Tibbetts M D, Samuel M A, Chang T S, et al. Stem cell therapy for retinal disease. Curr Opin Ophthalmol, 2012, 23: 226-234.
45. Phillips M I. Gene, stem cell, and future therapies for orphan diseases. Clin Pharmacol Ther, 2012, 92: 182-192.
46. Koenekoop R K, Lopez I, den Hollander A I, et al. Genetic testing for retinal dystrophies and dysfunctions: benefits, dilemmas and solutions. Clin Experiment Ophthalmol, 2007, 35: 473-485.
47. Riordan J R, Rommens J M, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 1989, 245: 1066-1073.
48. Gusella J F, Wexler N S, Conneally P M, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature, 1983, 306: 234-238.
49. Ng S B, Buckingham K J, Lee C, et al. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet, 2010, 42: 30-35.
50. Rabbani B, Mahdieh N, Hosomichi K, et al. Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J Hum Genet, 2012, 57: 621-632.
51. Wang Y, Guo L, Cai S P, et al. Exome sequencing identifies compound heterozygous mutations in CYP4V2 in a pedigree with retinitis pigmentosa. PLoS ONE, 2012, 7: e33673.
52. Hughes A E, Meng W, Lotery A J, et al. A novel GUCY2D mutation, V933A, causes central areolar choroidal dystrophy. Invest Ophthalmol Vis Sci, 2012, 53: 4748-4753.
53. Koenekoop R K, Wang H, Majewski J, et al. Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. Nat Genet, 2012, 44: 1035-1039.
54. Zhi D, Chen R. Statistical guidance for experimental design and data analysis of mutation detection in rare monogenic mendelian diseases by exome sequencing. PLoS ONE, 2012, 7: e31358.
55. Bowne S J, Sullivan L S, Mortimer S E, et al. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest Ophthalmol Vis Sci, 2006, 47: 34-42.
56. den Hollander A I, Heckenlively J R, van den Born L I, et al. Leber congenital amaurosis and retinitis pigmentosa with Coats-like exudative vasculopathy are associated with mutations in the crumbs homologue 1 (CRB1) gene. Am J Hum Genet, 2001, 69: 198-203.
57. den Hollander A I, Koenekoop R K, Mohamed M D, et al. Mutations in LCA5, encoding the ciliary protein lebercilin, cause Leber congenital amaurosis. Nat Genet, 2007, 39: 889-895.
58. den Hollander A I, Koenekoop R K, Yzer S, et al. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. Am J Hum Genet, 2006, 79: 556-561.
59. Dryja T P, Adams S M, Grimsby J L, et al. Null RPGRIP1 alleles in patients with Leber congenital amaurosis. Am J Hum Genet, 2001, 68: 1295-1298.
60. Estrada-Cuzcano A, Koenekoop R K, Coppieters F, et al. IQCB1 mutations in patients with Leber congenital amaurosis. Invest Ophthalmol Vis Sci, 2011, 52: 834-839.
61. Freund C L, Wang Q L, Chen S, et al. De novo mutations in the CRX homeobox gene associated with Leber congenital amaurosis. Nat Genet, 1998, 18: 311-312.
62. Friedman J S, Chang B, Kannabiran C, et al. Premature truncation of a novel protein, RD3, exhibiting subnuclear localization is associated with retinal degeneration. Am J Hum Genet, 2006, 79: 1059-1070.
63. Henderson R H, Williamson K A, Kennedy J S, et al. A rare de novo nonsense mutation in OTX2 causes early onset retinal dystrophy and pituitary dysfunction. Mol Vis, 2009, 15: 2442-2447.
64. Janecke A R, Thompson D A, Utermann G, et al. Mutations in RDH12 encoding a photoreceptor cell retinol dehydrogenase cause childhood-onset severe retinal dystrophy. Nat Genet, 2004, 36: 850-854.
65. Marlhens F, Bareil C, Griffoin J M, et al. Mutations in RPE65 cause Leber's congenital amaurosis. Nat Genet, 1997, 17: 139-141.
66. Mataftsi A, Schorderet D F, Chachoua L, et al. Novel TULP1 mutation causing leber congenital amaurosis or early onset retinal degeneration. Invest Ophthalmol Vis Sci, 2007, 48: 5160-5167.
67. Perrault I, Hanein S, Gerber S, et al. Retinal dehydrogenase 12 (RDH12) mutations in leber congenital amaurosis. Am J Hum Genet, 2004, 75: 639-646.
68. Perrault I, Rozet J M, Calvas P, et al. Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis. Nat Genet, 1996, 14: 461-464.
69. Sohocki M M, Bowne S J, Sullivan L S, et al. Mutations in a new photoreceptor-pineal gene on 17p cause Leber congenital amaurosis. Nat Genet, 2000, 24: 79-83.
70. Stone E M, Cideciyan A V, Aleman T S, et al. Variations in NPHP5 in patients with nonsyndromic leber congenital amaurosis and Senior-Loken syndrome. Arch Ophthalmol, 2011, 129: 81-87.
71. Wang H, den Hollander A I, Moayedi Y, et al. Mutations in SPATA7 cause Leber congenital amaurosis and juvenile retinitis pigmentosa. Am J Hum Genet, 2009, 84: 380-387.
72. Sergouniotis P I, Davidson A E, Mackay D S, et al. Recessive mutations in KCNJ13, encoding an inwardly rectifying potassium channel subunit, cause leber congenital amaurosis. Am J Hum Genet, 2011, 89: 183-190.
73. Daiger P, Rossiter B, Greenberg J, et al. Data services and software for identifying genes and mutations causing retinal degeneration. 1998, 39: 2.
74. Xi Q, Li L, Traboulsi E I, et al. Novel ABCA4 compound heterozygous mutations cause severe progressive autosomal recessive cone-rod dystrophy presenting as Stargardt disease. Mol Vis, 2009, 15: 638-645.
75. Kurg A, Tonisson N, Georgiou I, et al. Arrayed primer extension: solid-phase four-color DNA resequencing and mutation detection technology. Genet Test, 2000, 4: 1-7.
76. Henderson R H, Waseem N, Searle R, et al. An assessment of the apex microarray technology in genotyping patients with Leber congenital amaurosis and early-onset severe retinal dystrophy. Invest Ophthalmol Vis Sci, 2007, 48: 5684-5689.
77. Yzer S, Leroy B P, De Baere E, et al. Microarray-based mutation detection and phenotypic characterization of patients with Leber congenital amaurosis. Invest Ophthalmol Vis Sci, 2006, 47: 1167-1176.
78. Zernant J, Kulm M, Dharmaraj S, et al. Genotyping microarray (disease chip) for Leber congenital amaurosis: detection of modifier alleles. Invest Ophthalmol Vis Sci, 2005, 46: 3052-3059.
79. Bogni S, Schoni D, Constantinescu M, et al. Tissue fusion, a new opportunity for sutureless bypass surgery. Acta Neurochir Suppl, 2011, 112: 45-53.
80. Avila-Fernandez A, Cantalapiedra D, Aller E, et al. Mutation analysis of 272 Spanish families affected by autosomal recessive retinitis pigmentosa using a genotyping microarray. Mol Vis, 2010, 16: 2550-2558.
81. Blanco-Kelly F, Garcia-Hoyos M, Corton M, et al. Genotyping microarray: mutation screening in Spanish families with autosomal dominant retinitis pigmentosa. Mol Vis, 2012, 18: 1478-1483.
82. Allard R E. Retinitis pigmentosa-an overview. J Am Optom Assoc, 1983, 54: 793-800.
83. Franceschetti A, Dieterle P. Diagnostic and prognostic importance of the electroretinogram in tapetoretinal degeneration with reduction of the visual field and hemeralopia. Confin Neurol, 1954, 14: 184-186.
84. Dharmaraj S R, Silva E R, Pina A L, et al. Mutational analysis and clinical correlation in Leber congenital amaurosis. Ophthalmic Genet, 2000, 21: 135-150.
85. Stone E M. Leber congenital amaurosis-a model for efficient genetic testing of heterogeneous disorders: LXIV Edward Jackson Memorial Lecture. Am J Ophthalmol, 2007, 144: 791-811.
86. Xu F, Dong Q, Liu L, et al. Novel RPE65 mutations associated with Leber congenital amaurosis in Chinese patients. Mol Vis, 2012, 18: 744-750.
87. Seong M W, Kim S Y, Yu Y S, et al. Molecular characterization of Leber congenital amaurosis in Koreans. Mol Vis, 2008, 14: 1429-1436.
88. Downs K, Zacks D N, Caruso R, et al. Molecular testing for hereditary retinal disease as part of clinical care. Arch Ophthalmol, 2007, 125: 252-258.
89. Zernant J, Schubert C, Im K M, et al. Analysis of the ABCA4 gene by next-generation sequencing. Invest Ophthalmol Vis Sci, 2011, 52: 8479-8487.
90. Coppieters F, De Wilde B, Lefever S, et al. Massively parallel sequencing for early molecular diagnosis in Leber congenital amaurosis. Genet Med, 2012, 14: 576-585.
91. Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis, 2006, 1: 40.
92. Piersma A H, Hernandez L G, van Benthem J, et al. Reproductive toxicants have a threshold of adversity. Crit Rev Toxicol, 2011, 41: 545-554.
93. Pagon R A, Daiger S P. Retinitis pigmentosa overview. In: Pagon R A, Bird T D, Dolan C R, et al., eds. GeneReviews. Seattle: University of Washington, 1993.
94. Sohocki M M, Daiger S P, Bowne S J, et al. Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. Hum Mutat, 2001, 17: 42-51.
95. de Bie M K, van Rees J B, Herzog C A, et al. How to reduce the incidence of contrast induced acute kidney injury after cardiac invasive procedures, a review and practical recommendations. Curr Med Res Opin, 2011, 27: 1347-1357.
96. Gonzalez-Rodriguez M L, Rabasco A M. Charged liposomes as carriers to enhance the permeation through the skin. Expert Opin Drug Deliv, 2011, 8: 857-871.
97. Vijverberg S J, Koenderman L, Koster E S, et al. Biomarkers of therapy responsiveness in asthma: pitfalls and promises. Clin Exp Allergy, 2011, 41: 615-629.
98. Burke T R, Tsang S H. Allelic and phenotypic heterogeneity in ABCA4 mutations. Ophthalmic Genet, 2011, 32: 165-174.
99. Kaplan J, Gerber S, Larget-Piet D, et al. A gene for Stargardt's disease (fundus flavimaculatus) maps to the short arm of chromosome 1. Nat Genet, 1993, 5: 308-311.
100. Edwards A O, Donoso L A, Ritter R 3rd. A novel gene for autosomal dominant Stargardt-like macular dystrophy with homology to the SUR4 protein family. Invest Ophthalmol Vis Sci, 2001, 42: 2652-2663.
101. Vrabec T R, Tantri A, Edwards A, et al. Autosomal dominant Stargardt-like macular dystrophy: identification of a new family with a mutation in the ELOVL4 gene. Am J Ophthalmol, 2003, 136: 542-545.
102. Kniazeva M, Chiang M F, Morgan B, et al. A new locus for autosomal dominant stargardt-like disease maps to chromosome 4. Am J Hum Genet, 1999, 64: 1394-1399.
103. Quazi F, Lenevich S, Molday R S. ABCA4 is an N-retinylidene-phosphatidylethanolamine and phosphatidylethanolamine importer. Nat Commun, 2012, 3: 925.
104. Dornstauder B, Suh M, Kuny S, et al. Dietary docosahexaenoic acid supplementation prevents age-related functional losses and A2E accumulation in the retina. Invest Ophthalmol Vis Sci, 2012, 53: 2256-2265.
105. Rozet J M, Gerber S, Ghazi I, et al. Mutations of the retinal specific ATP binding transporter gene (ABCR) in a single family segregating both autosomal recessive retinitis pigmentosa RP19 and Stargardt disease: evidence of clinical heterogeneity at this locus. J Med Genet, 1999, 36: 447-451.
106. Jaakson K, Zernant J, Kulm M, et al. Genotyping microarray (gene chip) for the ABCR (ABCA4) gene. Hum Mutat, 2003, 22: 395-403.
107. Ernest P J, Boon C J, Klevering B J, et al. Outcome of ABCA4 microarray screening in routine clinical practice. Mol Vis, 2009, 15: 2841-2847.
108. Webster A R, Heon E, Lotery A J, et al. An analysis of allelic variation in the ABCA4 gene. Invest Ophthalmol Vis Sci, 2001, 42: 1179-1189.
109. Zaremba C M, Wiszniewski W, Lewis R A, et al. Identification of ABCA4 regulatory mutations in Stargart families. Invest Ophthalmol Vis Sci, 2005, 46: 1794.
110. Richards A J, McNinch A, Whittaker J, et al. Splicing analysis of unclassified variants in COL2A1 and COL11A1 identifies deep intronic pathogenic mutations. Eur J Hum Genet, 2012, 20: 552-558.
111. Klambauer G, Schwarzbauer K, Mayr A, et al. MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate. Nucleic Acids Res, 2012, 40: e69.
112. Nelson M R, Wegmann D, Ehm M G, et al. An abundance of rare functional variants in 202 drug target genes sequenced in 14002 people. Science, 2012, 337: 100-104.
113. Human Genomics Strategy Group. Building on our inheritance: genomic technology in healthcare. United Kindgom Department of Health, 2012.
114. Camerlengo T, Ozer H G, Onti-Srinivasan R, et al. From sequencer to supercomputer: an automatic pipeline for managing and processing next generation sequencing data. AMIA Summits Transl Sci Proc, 2012, 1-10.
115. Liu L, Li Y, Li S, et al. Comparison of next-generation sequencing systems. J Biomed Biotechnol, 2012, 251364.